Pacira | PCRX - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Assertio Holdings USD -3.05M 569K 2024-09
Astellas Pharma JPY 48.57B 85.97B 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cara Therapeutics USD -5.94M 3.55M 2025-09
Coherus Biosciences USD -39.08M 3.65M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
J&J USD 6.62B 1.03B 2026-03
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Omeros USD -35.41M 23.75M 2024-09
Pacira USD 3.19M 9.96M 2025-12
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
Teva Pharmaceutical Industries USD 758M 271M 2026-03
Xeris Pharmaceuticals USD 16.77M 10.04M 2025-12
Xoma USD -15.64M 5.56M 2024-09
Zoetis USD 835M 101M 2025-12